Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 23 | 2017 | 356 | 2.350 |
Why?
|
| Brain Neoplasms | 18 | 2019 | 638 | 1.420 |
Why?
|
| Gamma Rays | 3 | 2015 | 25 | 0.640 |
Why?
|
| Radiometry | 4 | 2015 | 39 | 0.590 |
Why?
|
| Radiation Oncology | 2 | 2013 | 10 | 0.570 |
Why?
|
| Meningioma | 4 | 2014 | 57 | 0.520 |
Why?
|
| Societies, Scientific | 1 | 2013 | 15 | 0.460 |
Why?
|
| Molecular Imaging | 1 | 2013 | 20 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2014 | 1324 | 0.430 |
Why?
|
| Meningeal Neoplasms | 3 | 2014 | 49 | 0.430 |
Why?
|
| Cranial Irradiation | 5 | 2017 | 93 | 0.410 |
Why?
|
| Brain | 5 | 2015 | 950 | 0.400 |
Why?
|
| Burns | 1 | 2012 | 100 | 0.380 |
Why?
|
| Models, Animal | 1 | 2011 | 164 | 0.380 |
Why?
|
| Skin | 1 | 2012 | 210 | 0.360 |
Why?
|
| Salvage Therapy | 6 | 2015 | 134 | 0.350 |
Why?
|
| Whole-Body Irradiation | 5 | 2015 | 50 | 0.340 |
Why?
|
| Radiation Injuries | 4 | 2017 | 72 | 0.270 |
Why?
|
| Nomograms | 3 | 2015 | 32 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2015 | 370 | 0.260 |
Why?
|
| Carmustine | 1 | 2015 | 8 | 0.250 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 40 | 0.240 |
Why?
|
| Trigeminal Neuralgia | 2 | 2015 | 33 | 0.240 |
Why?
|
| Male | 28 | 2017 | 19195 | 0.240 |
Why?
|
| Middle Aged | 21 | 2017 | 11868 | 0.230 |
Why?
|
| Humans | 30 | 2019 | 32024 | 0.230 |
Why?
|
| Retrospective Studies | 13 | 2015 | 3523 | 0.230 |
Why?
|
| Treatment Outcome | 13 | 2017 | 3317 | 0.230 |
Why?
|
| Female | 27 | 2019 | 19953 | 0.230 |
Why?
|
| Animals | 16 | 2019 | 7466 | 0.220 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2015 | 34 | 0.220 |
Why?
|
| Aged | 18 | 2017 | 10340 | 0.210 |
Why?
|
| Adult | 17 | 2017 | 9366 | 0.210 |
Why?
|
| Radiotherapy Dosage | 7 | 2017 | 101 | 0.210 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 761 | 0.200 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 409 | 0.180 |
Why?
|
| Treatment Failure | 6 | 2015 | 163 | 0.180 |
Why?
|
| Cognition Disorders | 2 | 2015 | 384 | 0.170 |
Why?
|
| Macaca mulatta | 3 | 2017 | 285 | 0.170 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 29 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1017 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2014 | 4000 | 0.150 |
Why?
|
| Calcium | 1 | 2019 | 307 | 0.150 |
Why?
|
| Follow-Up Studies | 8 | 2015 | 2280 | 0.140 |
Why?
|
| Aging | 2 | 2014 | 945 | 0.140 |
Why?
|
| Radiation Dosage | 3 | 2012 | 81 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 33 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 51 | 0.140 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 23 | 0.140 |
Why?
|
| Phantoms, Imaging | 2 | 2015 | 59 | 0.140 |
Why?
|
| Brain Injuries | 1 | 2017 | 93 | 0.130 |
Why?
|
| Calibration | 2 | 2015 | 27 | 0.130 |
Why?
|
| Facial Pain | 2 | 2014 | 21 | 0.130 |
Why?
|
| Epilepsy | 1 | 2017 | 82 | 0.130 |
Why?
|
| Pain Measurement | 2 | 2014 | 351 | 0.130 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 13 | 0.130 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2012 | 28 | 0.120 |
Why?
|
| Melanoma | 2 | 2015 | 164 | 0.120 |
Why?
|
| Brain Edema | 1 | 2014 | 15 | 0.120 |
Why?
|
| X-Rays | 2 | 2011 | 5 | 0.120 |
Why?
|
| Growth Hormone | 2 | 2013 | 13 | 0.120 |
Why?
|
| Brain Stem Neoplasms | 1 | 2014 | 4 | 0.120 |
Why?
|
| Dog Diseases | 1 | 2013 | 10 | 0.120 |
Why?
|
| Vein of Galen Malformations | 1 | 2013 | 4 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 25 | 0.110 |
Why?
|
| Cerebral Veins | 1 | 2013 | 12 | 0.110 |
Why?
|
| Survival Rate | 5 | 2017 | 885 | 0.110 |
Why?
|
| Health Physics | 1 | 2013 | 4 | 0.110 |
Why?
|
| Radiobiology | 1 | 2013 | 5 | 0.110 |
Why?
|
| Brain Death | 1 | 2013 | 27 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2012 | 200 | 0.110 |
Why?
|
| Radio Waves | 1 | 2012 | 8 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 26 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 594 | 0.100 |
Why?
|
| Temperature | 1 | 2012 | 55 | 0.100 |
Why?
|
| Neurilemmoma | 1 | 2012 | 16 | 0.100 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2012 | 17 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2019 | 599 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 154 | 0.100 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 5 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 765 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 757 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 319 | 0.100 |
Why?
|
| Collagen Diseases | 1 | 2011 | 5 | 0.100 |
Why?
|
| Macaca fascicularis | 2 | 2015 | 397 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2013 | 488 | 0.090 |
Why?
|
| Nanotubes, Carbon | 1 | 2011 | 23 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 34 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 311 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 66 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 114 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 407 | 0.090 |
Why?
|
| Time Factors | 5 | 2014 | 2152 | 0.090 |
Why?
|
| Iron | 1 | 2011 | 115 | 0.090 |
Why?
|
| Multiple Sclerosis | 1 | 2011 | 59 | 0.090 |
Why?
|
| Cognition | 1 | 2014 | 553 | 0.090 |
Why?
|
| Etidronic Acid | 1 | 2009 | 3 | 0.090 |
Why?
|
| Hippocampus | 1 | 2011 | 171 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 23 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2015 | 78 | 0.080 |
Why?
|
| Mice | 5 | 2019 | 2475 | 0.080 |
Why?
|
| Tumor Burden | 3 | 2014 | 60 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2011 | 156 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2009 | 82 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2009 | 94 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2009 | 69 | 0.080 |
Why?
|
| Osteoclasts | 1 | 2008 | 22 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 494 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 246 | 0.080 |
Why?
|
| Osteogenesis | 1 | 2008 | 82 | 0.080 |
Why?
|
| Subtraction Technique | 1 | 2008 | 10 | 0.080 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2007 | 15 | 0.080 |
Why?
|
| Rats | 4 | 2014 | 1596 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 51 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2008 | 33 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 61 | 0.070 |
Why?
|
| Ovary | 1 | 2007 | 58 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 725 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 113 | 0.070 |
Why?
|
| Rats, Inbred F344 | 3 | 2013 | 133 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 607 | 0.070 |
Why?
|
| Child | 3 | 2014 | 2441 | 0.070 |
Why?
|
| Young Adult | 4 | 2014 | 2615 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 159 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 918 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 323 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2011 | 1435 | 0.070 |
Why?
|
| Algorithms | 1 | 2008 | 496 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 470 | 0.060 |
Why?
|
| Recurrence | 2 | 2015 | 265 | 0.060 |
Why?
|
| Cause of Death | 2 | 2015 | 238 | 0.060 |
Why?
|
| Stereotaxic Techniques | 2 | 2014 | 23 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 565 | 0.050 |
Why?
|
| Radiography | 2 | 2015 | 377 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2010 | 766 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 3526 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 2 | 2013 | 33 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1200 | 0.050 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2019 | 26 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 61 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 99 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 532 | 0.040 |
Why?
|
| Models, Biological | 1 | 2019 | 391 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2016 | 25 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 120 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 80 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2013 | 2283 | 0.030 |
Why?
|
| Air | 1 | 2015 | 6 | 0.030 |
Why?
|
| Hypesthesia | 1 | 2015 | 9 | 0.030 |
Why?
|
| Water | 1 | 2015 | 56 | 0.030 |
Why?
|
| United States | 2 | 2015 | 3938 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 99 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 10 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 21 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 48 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 103 | 0.030 |
Why?
|
| Reoperation | 1 | 2015 | 227 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2015 | 149 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2014 | 11 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 124 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 30 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 20 | 0.030 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 8 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2013 | 9 | 0.030 |
Why?
|
| Dogs | 1 | 2013 | 120 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 82 | 0.030 |
Why?
|
| Macrophages | 1 | 2015 | 192 | 0.030 |
Why?
|
| History, 18th Century | 1 | 2013 | 2 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 37 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 508 | 0.030 |
Why?
|
| Pain | 1 | 2015 | 288 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2013 | 59 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 101 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 83 | 0.030 |
Why?
|
| Organ Size | 1 | 2013 | 210 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 186 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 687 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 87 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 163 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 63 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 103 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 11 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2012 | 65 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 40 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 179 | 0.020 |
Why?
|
| Facial Paralysis | 1 | 2011 | 7 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2011 | 12 | 0.020 |
Why?
|
| Ectodysplasins | 1 | 2011 | 2 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2011 | 7 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2011 | 11 | 0.020 |
Why?
|
| Neurogenesis | 1 | 2011 | 16 | 0.020 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2011 | 21 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 45 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2011 | 56 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 40 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1831 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 33 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 456 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 104 | 0.020 |
Why?
|
| Otitis Media | 1 | 2011 | 23 | 0.020 |
Why?
|
| Microglia | 1 | 2011 | 57 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 77 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 138 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 23 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 290 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 148 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 168 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 464 | 0.020 |
Why?
|
| Primates | 1 | 2010 | 104 | 0.020 |
Why?
|
| Glioma | 1 | 2011 | 136 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 247 | 0.020 |
Why?
|
| Systems Integration | 1 | 2009 | 11 | 0.020 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2009 | 17 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 981 | 0.020 |
Why?
|
| Artifacts | 1 | 2009 | 39 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 878 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1269 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 78 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 544 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 468 | 0.020 |
Why?
|
| Apoptosis | 1 | 2010 | 354 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2007 | 26 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2008 | 72 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 785 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 3869 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 833 | 0.020 |
Why?
|